Sofgen Pharma insider reports major indirect holdings

Sofgen Pharma S.A. director and 10% owner Manieu Alexandre Weinstein filed an initial Form 3 that reports large indirect holdings in the company through Hoche Partners Pharma Holdings LLC.

Rhea-AI Filing Summary

Sofgen Pharma S.A. director and 10% owner Manieu Alexandre Weinstein filed an initial Form 3 that reports large indirect holdings in the company through Hoche Partners Pharma Holdings LLC. The filing shows indirect ownership of 626,495,816 Ordinary Shares and a warrant to purchase 79,201,647 Ordinary Shares.

The warrant has an exercise price of $0.0631 per Ordinary Share and expires on April 9, 2035. Both the Ordinary Shares and the warrant are beneficially owned by Hoche Partners Pharma Holdings LLC, an entity controlled by Mr. Weinstein, and this filing reflects holdings rather than new market transactions.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Manieu Alexandre Weinstein

Role Director, 10% Owner

Type	Security	Shares	Price	Value
holding	Warrant to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrant to Purchase Ordinary Shares — 79,201,647 contracts (Indirect, By Hoche Partners Pharma Holdings LLC); Ordinary Shares — 626,495,816 shares (Indirect, By Hoche Partners Pharma Holdings LLC)

Footnotes (2)

1. F1. Represents Ordinary Shares beneficially owned by Hoche Partners Pharma Holdings LLC ("Hoche"), an entity controlled by Mr. Weinstein.
2. F2. Represents a warrant to purchase Ordinary Shares beneficially owned by Hoche, an entity controlled by Mr. Weinstein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing by Manieu Alexandre Weinstein for Sofgen Pharma (PROCF) disclose?

The Form 3 discloses Weinstein’s initial beneficial holdings in Sofgen Pharma. It reports indirect ownership, via Hoche Partners Pharma Holdings LLC, of 626,495,816 Ordinary Shares and a warrant linked to 79,201,647 additional Ordinary Shares at a $0.0631 exercise price.

How many Sofgen Pharma (PROCF) Ordinary Shares are reported as indirectly owned on this Form 3?

The filing reports indirect beneficial ownership of 626,495,816 Sofgen Pharma Ordinary Shares. These shares are held by Hoche Partners Pharma Holdings LLC, which is controlled by Manieu Alexandre Weinstein, and indicate a very substantial existing position rather than a new purchase or sale.

What are the key terms of the Sofgen Pharma (PROCF) warrant reported on this Form 3?

The Form 3 shows a warrant to purchase 79,201,647 Sofgen Pharma Ordinary Shares. The warrant has an exercise price of $0.0631 per share and an expiration date of April 9, 2035, and is indirectly owned through Hoche Partners Pharma Holdings LLC.

Are there any buy or sell transactions in the Sofgen Pharma (PROCF) Form 3 for Manieu Alexandre Weinstein?

The Form 3 does not report new buy or sell transactions. Instead, it lists existing indirect holdings in Sofgen Pharma, including Ordinary Shares and a warrant, with transactions classified as holdings and transaction share amounts left blank for those entries.

How is Hoche Partners Pharma Holdings LLC related to Manieu Alexandre Weinstein in the Sofgen Pharma (PROCF) filing?

The filing notes that the Ordinary Shares and the warrant are beneficially owned by Hoche Partners Pharma Holdings LLC. Footnotes explain that Hoche is an entity controlled by Manieu Alexandre Weinstein, so his reported ownership in Sofgen Pharma is held indirectly through this company.

What type of security besides Ordinary Shares is disclosed in the Sofgen Pharma (PROCF) Form 3?

Alongside Ordinary Shares, the Form 3 discloses a derivative security: a warrant to purchase Ordinary Shares. This warrant is indirectly owned, has an exercise price of $0.0631, covers 79,201,647 underlying shares, and expires on April 9, 2035, if not exercised earlier.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 07:39 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Manieu Alexandre Weinstein

(Last) (First) (Middle)

APT 8002, BURGENSTOCK HOTELS & RESORT

BURGENSTOCK 3

(Street)

OBBURGEN 6363

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	626,495,816	I	By Hoche Partners Pharma Holdings LLC(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to Purchase Ordinary Shares	04/09/2025	04/09/2035	Ordinary Shares	79,201,647	$0.0631	I	By Hoche Partners Pharma Holdings LLC(2)

Explanation of Responses:

1. Represents Ordinary Shares beneficially owned by Hoche Partners Pharma Holdings LLC ("Hoche"), an entity controlled by Mr. Weinstein.

2. Represents a warrant to purchase Ordinary Shares beneficially owned by Hoche, an entity controlled by Mr. Weinstein.

	/s/ Alexandre Weinstein Manieu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)